The pharmacological management of inflammatory bowel disease (IBD) over the last two
decades has transitioned from reliance on aminosalycilates, corticosteroids and …

Introduction: Crohn's disease (CD) and ulcerative colitis (UC) are chronic disabling
conditions. Monoclonal antibody therapy directed against tumor necrosis factor-alpha (anti …

Inflammatory bowel disease, including its 2 entities ulcerative colitis and Crohn's disease, is
a chronic medical condition characterized by the destructive inflammation of the intestinal …

Therapy for inflammatory bowel disease (IBD) has changed, with several new agents being
evaluated. The era of anti-tumor necrosis factor (anti-TNF) antibody therapy saw remarkable …

Over the last 2 decades, novel therapies targeting several immune pathways have been
developed for the treatment of patients with inflammatory bowel disease (IBD). Although anti …

Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disorder with an
unknown etiology. IBD is composed of two different disease entities: Crohn's disease (CD) …

The management of inflammatory bowel disease (IBD) has been transformed over the last
two decades by the arrival of tumor necrosis factor (TNF) antagonist agents. Recently …

Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases
which can be difficult to control with conventional therapies. A greater understanding of their …

Introduction: Efficacy and safety are key aspects when choosing therapies for patients with
inflammatory bowel diseases (IBD). While several randomized trials and indirect …

Background Over the last decade, biologics have gained an important place for the
treatment of moderate to severe inflammatory bowel disease (IBD), and many randomized …